APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cystic Fibrosis (CF) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cystic Fibrosis (CF) Therapeutics Market Analysis and Forecast 2026-2032

21 December 2025193 pages

Choose your research edition.

Industry ResearchCystic Fibrosis (CF) Therapeutics Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Cystic Fibrosis (CF) Therapeutics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Cystic Fibrosis (CF) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cystic Fibrosis (CF) Therapeutics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Cystic Fibrosis (CF) Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cystic Fibrosis (CF) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cystic Fibrosis (CF) Therapeutics include Teva Pharmaceutical Industries Ltd, Novartis AG, Merck & Co., Gilead, AbbVie,, AstraZeneca, Vertex Pharmaceuticalsorporated, F. Hoffmann-La Roche Ltd and ALLERGAN, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cystic Fibrosis (CF) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cystic Fibrosis (CF) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Cystic Fibrosis (CF) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cystic Fibrosis (CF) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cystic Fibrosis (CF) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cystic Fibrosis (CF) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Cystic Fibrosis (CF) Therapeutics Segment by Company

Teva Pharmaceutical Industries Ltd

Novartis AG

Merck & Co.

Gilead

AbbVie,

AstraZeneca

Vertex Pharmaceuticalsorporated

F. Hoffmann-La Roche Ltd

ALLERGAN

Alcresta

Alaxia

AIT (Advanced Inhalation Therapies)

Cystic Fibrosis (CF) Therapeutics Segment by Type

Bronchodilators

Mucolytics

Pancreatic enzyme supplements

CFTR modulators

Cystic Fibrosis (CF) Therapeutics Segment by Application

Oral drugs

Inhaled drugs

Cystic Fibrosis (CF) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cystic Fibrosis (CF) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cystic Fibrosis (CF) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cystic Fibrosis (CF) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cystic Fibrosis (CF) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cystic Fibrosis (CF) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cystic Fibrosis (CF) Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Bronchodilators Major Player Table 3. Mucolytics Major Player Table 4. Pancreatic enzyme supplements Major Player Table 5. CFTR modulators Major Player Table 6. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Oral drugs Major Player Table 8. Inhaled drugs Major Player Table 9. Cystic Fibrosis (CF) Therapeutics Industry Trends Table 10. Cystic Fibrosis (CF) Therapeutics Industry Drivers Table 11. Cystic Fibrosis (CF) Therapeutics Industry Opportunities and Challenges Table 12. Cystic Fibrosis (CF) Therapeutics Industry Restraints Table 13. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Cystic Fibrosis (CF) Therapeutics Market Share by Region (2021-2026) Table 16. Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Cystic Fibrosis (CF) Therapeutics Market Share by Region (2027-2032) Table 18. Global Cystic Fibrosis (CF) Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Players (2021-2026) Table 20. Global Cystic Fibrosis (CF) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Cystic Fibrosis (CF) Therapeutics Key Players Headquarters & Area Served Table 22. Global Cystic Fibrosis (CF) Therapeutics Players, Product Type & Application Table 23. Global Cystic Fibrosis (CF) Therapeutics Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Cystic Fibrosis (CF) Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Cystic Fibrosis (CF) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2021-2026) Table 30. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2027-2032) Table 31. Global Cystic Fibrosis (CF) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2021-2026) Table 35. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2027-2032) Table 36. Teva Pharmaceutical Industries Ltd Company Information Table 37. Teva Pharmaceutical Industries Ltd Business Overview Table 38. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 40. Teva Pharmaceutical Industries Ltd Recent Development Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis AG Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 45. Novartis AG Recent Development Table 46. Merck & Co. Company Information Table 47. Merck & Co. Business Overview Table 48. Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Merck & Co. Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 50. Merck & Co. Recent Development Table 51. Gilead Company Information Table 52. Gilead Business Overview Table 53. Gilead Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Gilead Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 55. Gilead Recent Development Table 56. AbbVie, Company Information Table 57. AbbVie, Business Overview Table 58. AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AbbVie, Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 60. AbbVie, Recent Development Table 61. AstraZeneca Company Information Table 62. AstraZeneca Business Overview Table 63. AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. AstraZeneca Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 65. AstraZeneca Recent Development Table 66. Vertex Pharmaceuticalsorporated Company Information Table 67. Vertex Pharmaceuticalsorporated Business Overview Table 68. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 70. Vertex Pharmaceuticalsorporated Recent Development Table 71. F. Hoffmann-La Roche Ltd Company Information Table 72. F. Hoffmann-La Roche Ltd Business Overview Table 73. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 75. F. Hoffmann-La Roche Ltd Recent Development Table 76. ALLERGAN Company Information Table 77. ALLERGAN Business Overview Table 78. ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. ALLERGAN Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 80. ALLERGAN Recent Development Table 81. Alcresta Company Information Table 82. Alcresta Business Overview Table 83. Alcresta Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Alcresta Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 85. Alcresta Recent Development Table 86. Alaxia Company Information Table 87. Alaxia Business Overview Table 88. Alaxia Cystic Fibrosis (CF) Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Alaxia Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 90. Alaxia Recent Development Table 91. AIT (Advanced Inhalation Therapies) Company Information Table 92. AIT (Advanced Inhalation Therapies) Business Overview Table 93. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 95. AIT (Advanced Inhalation Therapies) Recent Development Table 96. North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 110. China Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 111. China Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 112. China Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 113. China Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Cystic Fibrosis (CF) Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Cystic Fibrosis (CF) Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Cystic Fibrosis (CF) Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Cystic Fibrosis (CF) Therapeutics Image Figure 2. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cystic Fibrosis (CF) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Bronchodilators Image Figure 5. Mucolytics Image Figure 6. Pancreatic enzyme supplements Image Figure 7. CFTR modulators Image Figure 8. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Cystic Fibrosis (CF) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 10. Oral drugs Image Figure 11. Inhaled drugs Image Figure 12. Global Cystic Fibrosis (CF) Therapeutics Market Size (US$ Million) & (2021-2032) Figure 13. Global Cystic Fibrosis (CF) Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Cystic Fibrosis (CF) Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Cystic Fibrosis (CF) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2021-2032) Figure 20. Global Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2021-2032) Figure 23. North America Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032) Figure 25. North America Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032) Figure 26. North America Cystic Fibrosis (CF) Therapeutics Revenue Share by Country (2021-2032) Figure 27. United States Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032) Figure 32. Europe Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032) Figure 33. Europe Cystic Fibrosis (CF) Therapeutics Revenue Share by Country (2021-2032) Figure 34. Germany Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032) Figure 44. China Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032) Figure 45. Asia Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032) Figure 47. Asia Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032) Figure 48. Asia Cystic Fibrosis (CF) Therapeutics Revenue Share by Region (2021-2032) Figure 49. Japan Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032) Figure 57. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032) Figure 58. SAMEA Cystic Fibrosis (CF) Therapeutics Revenue Share by Country (2021-2032) Figure 59. Brazil Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Cystic Fibrosis (CF) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Bronchodilators
  • Mucolytics
  • Pancreatic enzyme supplements
  • CFTR modulators
Applications
  • Oral drugs
  • Inhaled drugs
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Merck & Co.
  • Gilead
  • AbbVie,
  • AstraZeneca
  • Vertex Pharmaceuticalsorporated
  • F. Hoffmann-La Roche Ltd
  • ALLERGAN
  • Alcresta
  • Alaxia
  • AIT (Advanced Inhalation Therapies)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cystic Fibrosis (CF) Therapeutics Market by Type
  3. 1.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Bronchodilators
  5. 1.2.3 Mucolytics
  6. 1.2.4 Pancreatic enzyme supplements
  7. 1.2.5 CFTR modulators
  8. 1.3 Cystic Fibrosis (CF) Therapeutics Market by Application
  9. 1.3.1 Global Cystic Fibrosis (CF) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Oral drugs
  11. 1.3.3 Inhaled drugs
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Cystic Fibrosis (CF) Therapeutics Market Dynamics
  1. 2.1 Cystic Fibrosis (CF) Therapeutics Industry Trends
  2. 2.2 Cystic Fibrosis (CF) Therapeutics Industry Drivers
  3. 2.3 Cystic Fibrosis (CF) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Cystic Fibrosis (CF) Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cystic Fibrosis (CF) Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Cystic Fibrosis (CF) Therapeutics Growth Trends by Region
  3. 3.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cystic Fibrosis (CF) Therapeutics Revenue by Players
  2. 4.1.1 Global Cystic Fibrosis (CF) Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cystic Fibrosis (CF) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cystic Fibrosis (CF) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cystic Fibrosis (CF) Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Cystic Fibrosis (CF) Therapeutics Players, Product Type & Application
  8. 4.5 Global Cystic Fibrosis (CF) Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cystic Fibrosis (CF) Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Cystic Fibrosis (CF) Therapeutics Tier 1, Tier 2, and Tier 3
5 Cystic Fibrosis (CF) Therapeutics Market Size by Type
  1. 5.1 Global Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2021-2032)
6 Cystic Fibrosis (CF) Therapeutics Market Size by Application
  1. 6.1 Global Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries Ltd
  2. 7.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Cystic Fibrosis (CF) Therapeutics Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Merck & Co.
  14. 7.3.1 Merck & Co. Company Information
  15. 7.3.2 Merck & Co. Business Overview
  16. 7.3.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co. Cystic Fibrosis (CF) Therapeutics Product Portfolio
  18. 7.3.5 Merck & Co. Recent Developments
  19. 7.4 Gilead
  20. 7.4.1 Gilead Company Information
  21. 7.4.2 Gilead Business Overview
  22. 7.4.3 Gilead Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Gilead Cystic Fibrosis (CF) Therapeutics Product Portfolio
  24. 7.4.5 Gilead Recent Developments
  25. 7.5 AbbVie,
  26. 7.5.1 AbbVie, Company Information
  27. 7.5.2 AbbVie, Business Overview
  28. 7.5.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AbbVie, Cystic Fibrosis (CF) Therapeutics Product Portfolio
  30. 7.5.5 AbbVie, Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca Cystic Fibrosis (CF) Therapeutics Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 Vertex Pharmaceuticalsorporated
  38. 7.7.1 Vertex Pharmaceuticalsorporated Company Information
  39. 7.7.2 Vertex Pharmaceuticalsorporated Business Overview
  40. 7.7.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product Portfolio
  42. 7.7.5 Vertex Pharmaceuticalsorporated Recent Developments
  43. 7.8 F. Hoffmann-La Roche Ltd
  44. 7.8.1 F. Hoffmann-La Roche Ltd Company Information
  45. 7.8.2 F. Hoffmann-La Roche Ltd Business Overview
  46. 7.8.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio
  48. 7.8.5 F. Hoffmann-La Roche Ltd Recent Developments
  49. 7.9 ALLERGAN
  50. 7.9.1 ALLERGAN Company Information
  51. 7.9.2 ALLERGAN Business Overview
  52. 7.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 ALLERGAN Cystic Fibrosis (CF) Therapeutics Product Portfolio
  54. 7.9.5 ALLERGAN Recent Developments
  55. 7.10 Alcresta
  56. 7.10.1 Alcresta Company Information
  57. 7.10.2 Alcresta Business Overview
  58. 7.10.3 Alcresta Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Alcresta Cystic Fibrosis (CF) Therapeutics Product Portfolio
  60. 7.10.5 Alcresta Recent Developments
  61. 7.11 Alaxia
  62. 7.11.1 Alaxia Company Information
  63. 7.11.2 Alaxia Business Overview
  64. 7.11.3 Alaxia Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Alaxia Cystic Fibrosis (CF) Therapeutics Product Portfolio
  66. 7.11.5 Alaxia Recent Developments
  67. 7.12 AIT (Advanced Inhalation Therapies)
  68. 7.12.1 AIT (Advanced Inhalation Therapies) Company Information
  69. 7.12.2 AIT (Advanced Inhalation Therapies) Business Overview
  70. 7.12.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product Portfolio
  72. 7.12.5 AIT (Advanced Inhalation Therapies) Recent Developments
8 North America
  1. 8.1 North America Cystic Fibrosis (CF) Therapeutics Revenue (2021-2032)
  2. 8.2 North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Cystic Fibrosis (CF) Therapeutics Revenue by Country
  11. 8.6.1 North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cystic Fibrosis (CF) Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country
  11. 9.6.1 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cystic Fibrosis (CF) Therapeutics Revenue (2021-2032)
  2. 10.2 China Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cystic Fibrosis (CF) Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Country
  11. 11.6.1 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cystic Fibrosis (CF) Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cystic Fibrosis (CF) Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst